NYSE:NVRO - Nevro Stock Price, Price Target & More

Get Started

$72.64 -0.43 (-0.59 %)

(As of 05/22/2018 02:09 AM ET)

Previous Close$72.64

Today's Range$72.34 - $74.52

52-Week Range$65.00 - $94.34

Volume348,185 shs

Average Volume425,711 shs

Market Capitalization$2.19 billion

P/E Ratio-58.11

Dividend YieldN/A

Beta-0.52

About Nevro (NYSE:NVRO)

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

SymbolNYSE:NVRO

CUSIPN/A

Webwww.nevro.com

Phone650-251-0005

Debt

Debt-to-Equity Ratio0.61

Current Ratio7.99

Quick Ratio6.17

Price-To-Earnings

Trailing P/E Ratio-58.11

Forward P/E Ratio-60.53

P/E GrowthN/A

Sales & Book Value

Annual Sales$326.67 million

Price / Sales6.67

Cash FlowN/A

Price / CashN/A

Book Value$8.41 per share

Price / Book8.64

Profitability

EPS (Most Recent Fiscal Year)($1.25)

Net Income$-36,650,000.00

Net Margins-11.53%

Return on Equity-16.32%

Return on Assets-9.07%

Miscellaneous

Employees676

Outstanding Shares29,980,000

Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro (NYSE:NVRO) issued its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.01. The medical equipment provider earned $97.96 million during the quarter, compared to analyst estimates of $96.87 million. Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. The firm's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.34) EPS. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Nevro.

What price target have analysts set for NVRO?

9 brokerages have issued 1-year target prices for Nevro's stock. Their forecasts range from $83.00 to $110.00. On average, they anticipate Nevro's stock price to reach $99.1250 in the next twelve months. View Analyst Ratings for Nevro.

Who are some of Nevro's key competitors?

Some companies that are related to Nevro include Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX) and Glaukos (GKOS).

Who are Nevro's key executives?

Nevro's management team includes the folowing people:

Mr. Rami Elghandour, Pres, CEO & Director (Age 39)
Mr. Andrew H. Galligan, Chief Financial Officer (Age 62)
Mr. Patrick Schmitz, VP of Operations (Age 58)
Mr. Doug Alleavitch, VP of Quality (Age 57)
Mr. Christofer Christoforou, VP of R&D (Age 48)

Has Nevro been receiving favorable news coverage?

News headlines about NVRO stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nevro earned a daily sentiment score of 0.00 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 47.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Nevro's major shareholders?

Nevro's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.99%), Franklin Resources Inc. (5.23%), Frontier Capital Management Co. LLC (2.79%), Wells Fargo & Company MN (2.76%), Kornitzer Capital Management Inc. KS (2.08%) and Zevenbergen Capital Investments LLC (2.05%). Company insiders that own Nevro stock include Andre Walker, Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Allianz Asset Management GmbH, Blair William & Co. IL, Oak Ridge Investments LLC, Frontier Capital Management Co. LLC, Wells Fargo & Company MN, Franklin Resources Inc. and Zevenbergen Capital Investments LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.

Which institutional investors are buying Nevro stock?

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Artisan Partners Limited Partnership, Cortina Asset Management LLC, State of Wisconsin Investment Board, Kornitzer Capital Management Inc. KS, BlackRock Inc., Elk Creek Partners LLC and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $72.64.

How big of a company is Nevro?

Nevro has a market capitalization of $2.19 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

MarketBeat Community Rating for Nevro (NVRO)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		292 (Vote Outperform)
Underperform Votes:		157 (Vote Underperform)
Total Votes:		449

MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Nevro (NYSE:NVRO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

9 Wall Street analysts have issued ratings and price targets for Nevro in the last 12 months. Their average twelve-month price target is $99.1250, suggesting that the stock has a possible upside of 36.46%. The high price target for NVRO is $110.00 and the low price target for NVRO is $83.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.75	2.86	2.86
Ratings Breakdown:	0 Sell Rating(s) 3 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$99.1250	$97.6250	$99.7143	$100.5714
Price Target Upside:	36.46% upside	12.34% upside	46.21% upside	13.99% upside

Nevro (NYSE:NVRO) Consensus Price Target History

Price Target History for Nevro (NYSE:NVRO)

Nevro (NYSE:NVRO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/8/2018	Canaccord Genuity	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $102.00	High
5/8/2018	JMP Securities	Reiterated Rating	Market Outperform ➝ Overweight	$120.00 ➝ $105.00	High
5/8/2018	Northland Securities	Downgrade	Outperform ➝ Market Perform		High
5/8/2018	Wells Fargo	Downgrade	Outperform ➝ Market Perform		High
4/4/2018	Goldman Sachs	Initiated Coverage	Neutral ➝ Neutral	$83.00	Low
12/14/2017	BMO Capital Markets	Reiterated Rating	Buy	$100.00	High
11/7/2017	Leerink Swann	Reiterated Rating	Outperform	$105.00 ➝ $110.00	N/A
8/8/2017	Morgan Stanley	Boost Price Target	Overweight	$87.00 ➝ $95.00	Medium
7/3/2017	JPMorgan Chase	Reiterated Rating	Overweight	$102.00	Low
5/14/2017	B. Riley	Downgrade	Neutral	$85.00	Low
8/11/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$98.00 ➝ $112.00	N/A
8/8/2016	Bank of America	Initiated Coverage	Buy	$100.00	N/A
7/19/2016	William Blair	Initiated Coverage	Outperform		N/A

(Data available from 5/22/2016 forward)

Nevro (NYSE:NVRO) Earnings History and Estimates Chart

Earnings by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE:NVRO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.86)
2019 EPS Consensus Estimate: ($0.43)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.34)	($0.13)	($0.24)
Q2 2018	2	($0.47)	($0.21)	($0.34)
Q3 2018	2	($0.41)	($0.14)	($0.28)
Q4 2018	1	($0.01)	($0.01)	($0.01)
Q1 2019	2	($0.50)	$0.04	($0.23)
Q2 2019	2	($0.36)	$0.04	($0.16)
Q3 2019	2	($0.20)	$0.01	($0.10)
Q4 2019	2	$0.01	$0.10	$0.06

Nevro (NYSE NVRO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018
5/7/2018	Q1 2018	($0.34)	($0.59)	$89.32 million	$87.64 million	View	N/A
2/22/2018	Q4 2017	($0.14)	($0.15)	$96.87 million	$97.96 million	View	Listen
11/6/2017	Q3 2017	($0.23)	($0.21)	$80.50 million	$82.26 million	View	N/A
8/7/2017	Q2 2017	($0.29)	($0.40)	$77.75 million	$78.02 million	View	Listen
5/8/2017	Q1 2017	($0.26)	($0.50)	$68.71 million	$68.40 million	View	Listen
2/23/2017	Q416	($0.20)	($0.34)	$66.41 million	$70.50 million	View	N/A
11/7/2016	Q316	($0.39)	($0.14)	$58.05 million	$60.92 million	View	Listen
8/8/2016	Q216	($0.47)	($0.31)	$45.11 million	$55.40 million	View	N/A
5/9/2016	Q116	($0.65)	($0.33)	$33.48 million	$41.65 million	View	N/A
2/29/2016	Q415	($0.56)	($0.51)	$32.88 million	$33.10 million	View	Listen
11/9/2015	Q315	($0.75)	($0.70)	$12.51 million	$15.40 million	View	N/A
8/6/2015	Q215	($0.89)	($0.77)	$9.65 million	$11.40 million	View	N/A
5/11/2015	Q1	($0.5430)	($0.57)	$8.20 million	$9.66 million	View	Listen
3/18/2015	Q4 2014	($0.51)	($0.59)		$9.72 million	View	N/A
12/2/2014	Q3 2014		($0.48)		$8.67 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Nevro (NYSE:NVRO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Nevro (NYSE NVRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.90%

Insider Trading History for Nevro (NYSE:NVRO)

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE NVRO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/14/2018	Andrew H. Galligan	CFO	Sell	7,000	$76.14	$532,980.00
3/7/2018	Wilfred E Jaeger	Director	Sell	160,542	$80.77	$12,966,977.34	1,518
3/5/2018	Wilfred E Jaeger	Director	Sell	42,116	$80.19	$3,377,282.04	1,518
3/1/2018	Andrew H. Galligan	CFO	Sell	7,000	$80.10	$560,700.00
3/1/2018	Wilfred E Jaeger	Director	Sell	10,000	$80.48	$804,800.00	1,518
2/27/2018	Wilfred E Jaeger	Director	Sell	14,458	$83.28	$1,204,062.24	1,518
11/14/2017	Andrew H Galligan	CFO	Sell	7,000	$75.11	$525,770.00
10/5/2017	Michael F Demane	Director	Sell	5,000	$93.50	$467,500.00
9/27/2017	Michael F. Demane	Director	Sell	5,000	$91.50	$457,500.00
9/14/2017	Wilfred E Jaeger	Director	Sell	16,467	$90.19	$1,485,158.73	1,518
9/13/2017	Michael F. Demane	Director	Sell	5,000	$89.50	$447,500.00
9/11/2017	Michael F. Demane	Director	Sell	25,000	$87.73	$2,193,250.00
8/24/2017	Wilfred E Jaeger	Director	Sell	52,520	$86.11	$4,522,497.20	1,518
8/21/2017	Wilfred E Jaeger	Director	Sell	40,343	$84.28	$3,400,108.04	1,518
8/16/2017	Wilfred E. Jaeger	Director	Sell	79,657	$82.74	$6,590,820.18
8/15/2017	Wilfred E. Jaeger	Director	Sell	29,665	$82.54	$2,448,549.10
8/14/2017	Andrew H. Galligan	CFO	Sell	7,000	$82.31	$576,170.00
8/14/2017	Wilfred E. Jaeger	Director	Sell	25,255	$82.40	$2,081,012.00
5/15/2017	Andrew H. Galligan	CFO	Sell	7,500	$75.30	$564,750.00
5/2/2017	Michael F Demane	Director	Sell	29,800	$96.07	$2,862,886.00	501,795
5/1/2017	Rami Elghandour	CEO	Sell	10,000	$95.03	$950,300.00
4/4/2017	Michael Enxing	VP	Sell	1,500	$93.53	$140,295.00
4/4/2017	Michael F Demane	Director	Sell	22,200	$93.39	$2,073,258.00	517,795
4/3/2017	Andrew H. Galligan	CFO	Sell	30,000	$94.46	$2,833,800.00
3/6/2017	Michael Enxing	VP	Sell	38,500	$91.01	$3,503,885.00
3/3/2017	Wilfred E Jaeger	Director	Sell	43,980	$95.03	$4,179,419.40
1/4/2017	Michael Enxing	VP	Sell	1,500	$75.88	$113,820.00
12/5/2016	Michael Enxing	VP	Sell	1,500	$76.38	$114,570.00
11/15/2016	Andrew H Galligan	CFO	Sell	7,500	$86.90	$651,750.00	33,315
10/10/2016	Rami Elghandour	CEO	Sell	3,000	$100.00	$300,000.00
10/6/2016	Michael F Demane	Director	Sell	139,514	$97.46	$13,597,034.44	532,425
10/4/2016	Michael Enxing	VP	Sell	1,500	$99.31	$148,965.00	39,463
8/22/2016	Doug Alleavitch	VP	Sell	3,000	$100.00	$300,000.00	5,961
8/22/2016	Wilfred E Jaeger	Director	Sell	154,840	$97.79	$15,141,803.60
8/17/2016	Wilfred E Jaeger	Director	Sell	155,160	$97.31	$15,098,619.60
8/15/2016	Andrew H Galligan	CFO	Sell	7,500	$97.71	$732,825.00	30,079
8/10/2016	Doug Alleavitch	VP	Sell	2,500	$95.00	$237,500.00	6,961
8/9/2016	Michael F Demane	Director	Sell	26,667	$91.50	$2,440,030.50	499,252
8/4/2016	Michael Enxing	VP	Sell	1,500	$82.06	$123,090.00	39,463
7/29/2016	Doug Alleavitch	VP	Sell	1,000	$85.00	$85,000.00	7,961
7/29/2016	Michael F Demane	Director	Sell	13,333	$84.00	$1,119,972.00	505,919
7/11/2016	Doug Alleavitch	VP	Sell	2,000	$80.00	$160,000.00	8,961
7/11/2016	Michael F Demane	Director	Sell	13,333	$79.00	$1,053,307.00	512,586
7/5/2016	Michael Enxing	VP	Sell	1,500	$75.39	$113,085.00	39,463
7/1/2016	Michael F Demane	Director	Sell	13,333	$74.00	$986,642.00	519,253
6/8/2016	Doug Alleavitch	VP	Sell	1,000	$75.00	$75,000.00	9,961
6/8/2016	Rami Elghandour	CEO	Sell	7,000	$76.59	$536,130.00	71,180
6/6/2016	Michael Enxing	VP	Sell	1,500	$73.29	$109,935.00	39,463
6/2/2016	Andre Walker	VP	Sell	4,000	$73.50	$294,000.00	4,197
6/1/2016	Doug Alleavitch	VP	Sell	500	$72.00	$36,000.00	10,961
5/18/2016	Wilfred E Jaeger	Director	Sell	112,983	$64.68	$7,307,740.44
5/16/2016	Andrew H Galligan	CFO	Sell	10,000	$64.78	$647,800.00	40,000
5/16/2016	Michael F Demane	CEO	Sell	39,999	$64.77	$2,590,735.23	525,920
5/12/2016	Rami Elghandour	President	Sell	7,000	$63.93	$447,510.00	68,024
5/4/2016	Michael Enxing	VP	Sell	1,500	$65.06	$97,590.00	38,913
4/4/2016	Michael Enxing	VP	Sell	8,767	$61.59	$539,959.53	46,180
4/1/2016	Rami Elghandour	President	Sell	7,000	$60.99	$426,930.00	71,180
1/11/2016	Andre Walker	VP	Sell	7,987	$70.75	$565,080.25	470
1/4/2016	Doug Alleavitch	VP	Sell	2,514	$66.47	$167,105.58	11,470
12/17/2015	Andre Walker	VP	Sell	13	$69.00	$897.00	470
12/7/2015	Rami Elghandour	President	Sell	3,500	$61.82	$216,370.00
12/2/2015	Andre Walker	VP	Sell	1,000	$64.00	$64,000.00	470
12/1/2015	Andre Walker	VP	Sell	8,000	$59.50	$476,000.00	470
11/30/2015	Andre Walker	VP	Sell	6,000	$58.50	$351,000.00	470
11/30/2015	Rami Elghandour	President	Sell	3,500	$60.00	$210,000.00
11/24/2015	Andre Walker	VP	Sell	1,000	$55.00	$55,000.00	470
11/23/2015	Andre Walker	VP	Sell	1,000	$54.00	$54,000.00	470
11/23/2015	Wilfred E Jaeger	Director	Sell	25,000	$53.48	$1,337,000.00
11/18/2015	Wilfred E Jaeger	Director	Sell	175,000	$52.24	$9,142,000.00
11/16/2015	Michael F Demane	CEO	Sell	26,667	$50.52	$1,347,216.84	573,941
11/13/2015	Brad Vale	Director	Buy	2,000	$50.76	$101,520.00	2,000
9/17/2015	Andre Walker	VP	Sell	4,000	$50.75	$203,000.00
9/2/2015	Michael F Demane	CEO	Sell	40,001	$45.11	$1,804,445.11	600,608
6/8/2015	& Johnson Johnson	Major Shareholder	Sell	1,010,265	$47.94	$48,432,104.10
6/8/2015	Bay City Capital Llc	Insider	Sell	491,835	$47.94	$23,578,569.90
6/8/2015	Wilfred E Jaeger	Director	Sell	393,468	$47.94	$18,862,855.92
11/12/2014	& Johnson Johnson	Major Shareholder	Buy	40,000	$18.00	$720,000.00
11/12/2014	A/S Novo	Insider	Buy	215,000	$18.00	$3,870,000.00

(Data available from 1/1/2013 forward)

Nevro (NYSE NVRO) News Headlines

Source:

Date	Headline
	Nevro (NVRO) Downgraded by ValuEngine www.americanbankingnews.com - May 17 at 5:51 PM
	Form 4 NEVRO CORP For: May 14 Filed by: Galligan Andrew H www.streetinsider.com - May 17 at 5:18 PM
	Andrew H. Galligan Sells 7,000 Shares of Nevro (NVRO) Stock www.americanbankingnews.com - May 16 at 10:16 PM
	Nevro Recognized as a "Best Place to Work" in the Bay Area finance.yahoo.com - May 14 at 4:48 PM
	Nevro (NVRO) Expected to Post Quarterly Sales of $96.69 Million www.americanbankingnews.com - May 12 at 3:50 AM
	Zacks: Analysts Expect Nevro (NVRO) Will Announce Earnings of -$0.30 Per Share www.americanbankingnews.com - May 10 at 9:22 AM
	Analysts Set Expectations for Nevro's Q2 2018 Earnings (NVRO) www.americanbankingnews.com - May 10 at 6:36 AM
	Nevro Expected to Earn Q2 2018 Earnings of ($0.21) Per Share (NVRO) www.americanbankingnews.com - May 10 at 6:36 AM
	Edited Transcript of NVRO earnings conference call or presentation 7-May-18 8:30pm GMT finance.yahoo.com - May 9 at 4:50 PM
	Nevro (NVRO) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - May 9 at 12:09 PM
	Q4 2019 Earnings Estimate for Nevro (NVRO) Issued By Leerink Swann www.americanbankingnews.com - May 9 at 9:47 AM
	William Blair Weighs in on Nevro's Q4 2019 Earnings (NVRO) www.americanbankingnews.com - May 9 at 9:47 AM
	Wells Fargo Downgrades Nevro Corp (NVRO) to Market Perform www.streetinsider.com - May 9 at 9:09 AM
	Nevro (NVRO) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - May 8 at 11:26 PM
	Nevro Shares Cross Below 200 DMA www.nasdaq.com - May 8 at 4:48 PM
	Oversold Conditions For Nevro www.nasdaq.com - May 8 at 4:48 PM
	Why Nevro Corp. Is Sinking Today finance.yahoo.com - May 8 at 4:48 PM
	Nevro (NVRO) Lowered to "Market Perform" at Northland Securities www.americanbankingnews.com - May 8 at 3:45 PM
	Nevro (NVRO) Price Target Cut to $105.00 www.americanbankingnews.com - May 8 at 3:39 PM
	Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report feeds.benzinga.com - May 8 at 3:18 PM
	Nevro (NVRO) Downgraded by Wells Fargo to "Market Perform" www.americanbankingnews.com - May 8 at 1:41 PM
	Nevro (NVRO) Price Target Lowered to $102.00 at Canaccord Genuity www.americanbankingnews.com - May 8 at 10:22 AM
	Nevro's (NVRO) CEO Rami Elghandour on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 8 at 9:03 AM
	Investors Purchase High Volume of Call Options on Nevro (NVRO) www.americanbankingnews.com - May 8 at 6:52 AM
	Nevro Target of Unusually High Options Trading (NVRO) www.americanbankingnews.com - May 8 at 6:52 AM
	Nevro (NVRO) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS www.americanbankingnews.com - May 7 at 6:26 PM
	Nevro Reports First Quarter 2018 Financial Results finance.yahoo.com - May 7 at 4:56 PM
	Nevro: 1Q Earnings Snapshot finance.yahoo.com - May 7 at 4:56 PM
	Nevro (NVRO) and Orthopediatrics (KIDS) Head to Head Review www.americanbankingnews.com - May 7 at 3:32 AM
	Nevro to Present at the Bank of America Merrill Lynch 2018 Health Care Conference finance.yahoo.com - May 2 at 4:51 PM
	Nevro (NVRO) Scheduled to Post Earnings on Monday www.americanbankingnews.com - April 30 at 2:38 AM
	Nevro (NVRO) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - April 29 at 5:35 AM
	Zacks Investment Research Upgrades Nevro (NVRO) to Hold www.americanbankingnews.com - April 26 at 6:10 AM
	Zacks: Brokerages Anticipate Nevro (NVRO) Will Post Quarterly Sales of $88.45 Million www.americanbankingnews.com - April 25 at 5:56 AM
	Nevro to Report Operating Results for the First Quarter 2018 finance.yahoo.com - April 23 at 4:42 PM
	Zacks: Analysts Anticipate Nevro (NVRO) to Post -$0.34 EPS www.americanbankingnews.com - April 23 at 1:14 AM
	Nevro (NVRO) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 14 at 12:53 PM
	Morgan Stanley Boosts Nevro (NVRO) Price Target to $95.00 www.americanbankingnews.com - April 12 at 5:45 PM
	Establishment Labs Appoints Jeremy Livianu as General Counsel globenewswire.com - April 12 at 9:53 AM
	Zacks Investment Research Lowers Nevro (NVRO) to Hold www.americanbankingnews.com - April 10 at 7:17 PM
	BRIEF-Nevro Corp Says CEO Rami Elghandour's FY 2017 Total Compensation Was $13.2 Mln www.reuters.com - April 8 at 10:24 AM
	$88.57 Million in Sales Expected for Nevro Corp (NVRO) This Quarter www.americanbankingnews.com - April 8 at 4:48 AM
	Investors Buy Large Volume of Call Options on Nevro (NVRO) www.americanbankingnews.com - April 6 at 7:24 AM
	Zacks: Analysts Expect Nevro Corp (NVRO) to Post -$0.34 Earnings Per Share www.americanbankingnews.com - April 6 at 3:08 AM
	Nevro (NVRO) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 5 at 11:52 PM
	Nevro (NVRO) Earns Hold Rating from Analysts at Goldman Sachs www.americanbankingnews.com - April 4 at 8:04 AM
	Nevro Corp (NVRO) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 4 at 5:36 AM
	Nevro (NVRO) Raised to Hold at ValuEngine www.americanbankingnews.com - April 3 at 11:04 AM
	Nevro (NVRO) Raised to "C-" at TheStreet www.americanbankingnews.com - April 1 at 11:23 AM
	These medical devices offer hope for treating chronic pain without opioids www.cnbc.com - March 29 at 4:46 PM

Nevro (NYSE:NVRO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Nevro (NYSE:NVRO) Income Statement, Balance Sheet and Cash Flow Statement

Nevro (NYSE NVRO) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff